Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region.
BACKGROUND
To asses carbon ion radiation therapy (RT) performed as re-irradiation in 28 patients with recurrent tumors.


METHODS
Twenty-eight patients were treated with carbon ion RT as re-irradiation for recurrent chordoma and chondrosarcoma of the skull base (n=16 and n=2), one chordoma and one chondrosarcoma of the os sacrum, high-risk meningioma (n=3), adenoid-cystic carcinoma (n=4) as well as one SCCHN. All patients were treated using active raster scanning, and treatment planning was performed on CT- and MRI-basis. All patients were followed prospectively during follow-up.


RESULTS
In all patients re-irradiation could be applied safely without interruptions. For skull base tumors, local tumor control after re-irradiation was 92% at 24 months and 64% at 36 months. Survival after re-irradiation was 86% at 24 months, and 43% at 60 months. In all three meningiomas treated with C12 for re-irradiation, the tumor recurrence was located within the former RT-field. Two patients developed tumor progression at 6 months, and in one patient the tumor remained stable for 67 months. In patients with head-and-neck tumors, three patients developed local tumor progression at 12, 24 and 29 months after re-irradiation. Median local progression-free survival was 24 months. For sacral tumors, re-irradiation offered palliation with tumor control for 24 and 36 months.


CONCLUSIONS
Due to the physical characteristics particle therapy offers a new treatment modality in cases with tumor recurrences. With carbon ions, the additional biological benefits may be exploited for long-term tumor control. Further evaluation in a larger patients' cohort will be performed in the future.
Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany. Stephanie.Combs@med.uni-heidelberg.de
Stephanie E
SE
Combs
Adriana
A
Kalbe
Anna
A
Nikoghosyan
Benjamin
B
Ackermann
Oliver
O
Jäkel
Thomas
T
Haberer
Jürgen
J
Debus
D000328:Adult; D000368:Aged; D002244:Carbon / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000532:radiotherapy*; D002813:Chondrosarcoma / Q000532:radiotherapy*; D002817:Chordoma / Q000532:radiotherapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D063193:Heavy Ion Radiotherapy; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000532:radiotherapy*; D008579:Meningioma / Q000532:radiotherapy*; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012445:Sacrococcygeal Region; D019292:Skull Base Neoplasms / Q000532:radiotherapy*
D002244:Carbon